Business Description
abrdn Life Sciences Investors
NAICS : 523930
SIC : 6282
ISIN : US87911K1007
Description
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | N/A | |||||
Equity-to-Asset | 1 | |||||
Debt-to-EBITDA | N/A | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 5/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -45.7 | |||||
3-Year EPS without NRI Growth Rate | -46.5 | |||||
3-Year Book Growth Rate | -9.5 |
Momentum Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 50.76 | |||||
9-Day RSI | 43.94 | |||||
14-Day RSI | 42.38 | |||||
6-1 Month Momentum % | 10.94 | |||||
12-1 Month Momentum % | 27 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History |
---|
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 13.19 | |||||
Dividend Payout Ratio | 0.99 | |||||
3-Year Dividend Growth Rate | -4.5 | |||||
Forward Dividend Yield % | 14.13 | |||||
5-Year Yield-on-Cost % | 11.21 | |||||
3-Year Average Share Buyback Ratio | -3.9 | |||||
Shareholder Yield % | 13.35 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Net Margin % | 97.13 | |||||
ROE % | 9.2 | |||||
ROA % | 9.11 | |||||
Years of Profitability over Past 10-Year | 5 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 10.54 | |||||
PE Ratio without NRI | 10.54 | |||||
PS Ratio | 9.6 | |||||
PB Ratio | 0.88 | |||||
Price-to-Tangible-Book | 0.88 | |||||
EV-to-Revenue | 9.67 | |||||
Price-to-Graham-Number | 0.64 | |||||
Forward Rate of Return (Yacktman) % | -5.24 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:HQL
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
abrdn Life Sciences Investors Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 39.951 | ||
EPS (TTM) ($) | 1.34 | ||
Beta | 0.75 | ||
Volatility % | 17 | ||
14-Day RSI | 42.38 | ||
14-Day ATR ($) | 0.272165 | ||
20-Day SMA ($) | 14.485 | ||
12-1 Month Momentum % | 27 | ||
52-Week Range ($) | 11.67 - 15.8999 | ||
Shares Outstanding (Mil) | 27.35 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 5 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
abrdn Life Sciences Investors Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
abrdn Life Sciences Investors Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
abrdn Life Sciences Investors Frequently Asked Questions
What is abrdn Life Sciences Investors(HQL)'s stock price today?
When is next earnings date of abrdn Life Sciences Investors(HQL)?
Does abrdn Life Sciences Investors(HQL) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |